Results 1 to 10 of about 5,449 (190)
IDCases, 2020 Cefiderocol is a novel siderophore cephalosporin antibacterial with activity against carbapenem-resistant Gram-negative bacteria including Pseudomonas aeruginosa.
Pegah Shakeraneh, Timothy Endy
exaly +4 more sources
New mutations in genes associated with cefiderocol resistance in a clinical isolate of Pseudomonas aeruginosa [PDF]
Клиническая микробиология и антимикробная химиотерапия, 2023 Objective. To assess the effects of chromosomal mutations on emergence of cefiderocol resistance among Pseudomonas aeruginosa clinical isolates. Materials and Methods.
Bocharova Yu.A. +3 more
doaj +3 more sources
Microbiology Spectrum, 2022 Cefiderocol is a novel siderophore cephalosporin exhibiting potent antimicrobial activities. Although cefiderocol has not been approved in China, resistance is emerging.
Xueqing Wu +2 more
exaly +3 more sources
Microbiology Spectrum, 2023 Klebsiella pneumoniae AR 0047 from the CDC and FDA Antibiotic Resistance Isolate Bank is resistant to cefiderocol, a siderophore-conjugated cephalosporin.
En Huang
exaly +3 more sources
Cefiderocol nonsusceptibility among carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: data from the 2024 Antimicrobial Testing Leadership and Surveillance (ATLAS) program [PDF]
Antimicrobial Agents and ChemotherapyWe evaluated cefiderocol activity against carbapenem-resistant Pseudomonas aeruginosa (CRPA) and carbapenem-resistant Acinetobacter baumannii (CRAB), characterized the β-lactamase gene profiles of cefiderocol-nonsusceptible CRPA by metallo-β-lactamase ...
Po-Wei Chiu +6 more
doaj +2 more sources
Clonal lineage and biofilm growth shape cefiderocol activity in Acinetobacter baumannii from oncology patients [PDF]
Frontiers in Cellular and Infection MicrobiologyIntroductionAcinetobacter baumannii is a leading cause of healthcare-associated infections in immunocompromised patients and frequently exhibits multidrug resistance.
Ilaria Cavallo +11 more
doaj +2 more sources
Combinatorial effects of a novel SHV-248 variant, NDM-5, and ompK35 deficiency drive high-level cefiderocol resistance in Klebsiella pneumoniae [PDF]
Microbiology SpectrumCefiderocol holds significant therapeutic value against metallo-β-lactamase-producing Enterobacterales. However, reduced susceptibility to cefiderocol in NDM-producing strains is increasingly observed.
Chuwen Zhao +7 more
doaj +2 more sources
Revista Española de Quimioterapia, 2022 Cefiderocol is a new siderophore cephalosporin with potent in vitro activity against gram-negative bacilli including Enterobacterales that produce all kinds of carbapenemases and non-fermenting Gram-negative with difficult-to-treat resistance. As a β-lactam, its efficacy is optimized in extended-perfusion and requires dose adjustment in renal ...
Soriano, María Cruz +2 more
+5 more sources
Frontiers in Pharmacology, 2022 Cefiderocol is a novel synthetic siderophore-conjugated antibiotic that hijacks the bacterial iron transport systems facilitating drug entry into cells, achieving high periplasmic concentrations.
Chuanhai Wang +3 more
doaj +1 more source
Antibiotics, 2022 The role of β-lactamases in reduced susceptibility or resistance to cefiderocol has been supported by recent reports. The purpose of this study was to investigate the in vitro impact of clinically available β-lactamase inhibitors on cefiderocol activity ...
Gabriele Bianco +7 more
doaj +1 more source